Market Size of Japan Diabetes Drugs Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 3.15 Billion |
| Market Size (2029) | USD 4.03 Billion |
| CAGR (2024 - 2029) | 4.98 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Japan Diabetes Drugs Market Analysis
The Japan Diabetes Drugs Market size is estimated at USD 3.15 billion in 2024, and is expected to reach USD 4.03 billion by 2029, growing at a CAGR of 4.98% during the forecast period (2024-2029).
While Type 1 diabetes is caused by an immune system malfunction, Type 2 diabetes is linked to leading a sedentary lifestyle, which results in the development of inherent resistance to insulin. Hence, Type 1 diabetes can be characterized as insulin-requiring, while Type 2 diabetes can be characterized as insulin-dependent diabetes.
Japan has one of the largest elderly populations in the world which is more susceptible to the onset of type 2 diabetes. As Japan's population continues to age, the prevalence of diabetes increases as well. The monitoring and management of blood glucose levels are on the rise, to avoid negative consequences, such as cardiovascular diseases, kidney disorders, and many other conditions.
The prevalence of diabetes is increasing among the population, especially the elderly population, owing to unhealthy diets, obese population, and sedentary lifestyles. Various studies were conducted to assess the prescription patterns of oral antidiabetic drugs in Japanese patients with type 2 diabetes.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Japan Diabetes Drugs Industry Segmentation
Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Japan Diabetes Drugs Market is segmented into insulin drugs, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs. The report offers the value (in USD) and volume (in units) for the above segments.
| Insulins | |
| Basal or Long Acting Insulins | |
| Bolus or Fast Acting Insulins | |
| Traditional Human Insulins | |
| Biosimilar Insulins |
| Oral Anti-diabetic drugs | |
| Biguanides | |
| Alpha-Glucosidase Inhibitors | |
| Dopamine D2 receptor agonist | |
| SGLT-2 inhibitors | |
| DPP-4 inhibitors | |
| Sulfonylureas | |
| Meglitinides |
| Non-Insulin Injectable drugs | |
| GLP-1 receptor agonists | |
| Amylin Analogue |
| Combination drugs | |
| Insulin combinations | |
| Oral Combinations |
Japan Diabetes Drugs Market Size Summary
The Japan Diabetes Drugs Market is poised for significant growth, driven by the increasing prevalence of diabetes, particularly type 2, among the aging population. This rise is attributed to factors such as unhealthy diets, obesity, and sedentary lifestyles, which are prevalent in Japan. The market is characterized by a strong focus on oral anti-diabetic drugs, which are preferred due to their efficacy, safety, and cost-effectiveness. These drugs play a crucial role in managing blood glucose levels and reducing the risk of complications associated with diabetes, such as cardiovascular diseases and kidney disorders. The Japanese healthcare system supports this market growth through disease management programs and public health policies aimed at promoting lifestyle and dietary changes to prevent adult-onset diabetes.
The market landscape is consolidated, with major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca leading the charge. These companies are actively engaged in strategy-based mergers and acquisitions to expand their market presence and enhance revenue streams. The introduction of innovative products, such as SGLT-2 inhibitors, has further bolstered the market, offering effective management of blood glucose levels and cardiovascular risk factors. The economic burden of diabetes, exacerbated by co-morbidities, underscores the importance of well-organized medical insurance systems in Japan, which cover all medical fees and facilitate easy access to healthcare services. This supportive environment, coupled with ongoing advancements in diabetes management technologies, is expected to sustain the market's growth trajectory in the coming years.
Japan Diabetes Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Insulins
-
2.1.1 Basal or Long Acting Insulins
-
2.1.2 Bolus or Fast Acting Insulins
-
2.1.3 Traditional Human Insulins
-
2.1.4 Biosimilar Insulins
-
-
2.2 Oral Anti-diabetic drugs
-
2.2.1 Biguanides
-
2.2.2 Alpha-Glucosidase Inhibitors
-
2.2.3 Dopamine D2 receptor agonist
-
2.2.4 SGLT-2 inhibitors
-
2.2.5 DPP-4 inhibitors
-
2.2.6 Sulfonylureas
-
2.2.7 Meglitinides
-
-
2.3 Non-Insulin Injectable drugs
-
2.3.1 GLP-1 receptor agonists
-
2.3.2 Amylin Analogue
-
-
2.4 Combination drugs
-
2.4.1 Insulin combinations
-
2.4.2 Oral Combinations
-
-
Japan Diabetes Drugs Market Size FAQs
How big is the Japan Diabetes Drugs Market?
The Japan Diabetes Drugs Market size is expected to reach USD 3.15 billion in 2024 and grow at a CAGR of 4.98% to reach USD 4.03 billion by 2029.
What is the current Japan Diabetes Drugs Market size?
In 2024, the Japan Diabetes Drugs Market size is expected to reach USD 3.15 billion.
